CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832

Sorafenib in Advanced Hepatocellular Carcinoma

정, 재. (2008) · Cited by 5,586

The senescence-associated secretory phenotype: the dark side of tumor suppression

Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens

Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684

Hepatocellular carcinoma

Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051

Genetic landscape and biomarkers of hepatocellular carcinoma

Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080

Targeted therapy for hepatocellular carcinoma

Huang, A., Yang, X., Chung, W. Y., Dennison, A. R., & Zhou, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00264-x · Cited by 767

CDK inhibitors in cancer therapy, an overview of recent development.

Zhang, M., Zhang, L., Hei, R., Li, X., Cai, H., Wu, X., Zheng, Q., & Cai, C. (2021) · PubMed Central · Cited by 280

CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma

Chen, Y., Li, L., Lan, J., Cui, Y., Rao, X., Zhao, J., Xing, T., Ju, G., Song, G., Lou, J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01466-9 · Cited by 126

Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery

Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 101

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer

Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95

Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor

Niu, T., Li, K., Li, J., Zhou, Z., Hong, J.-E., Chen, X., Dong, X., He, Q., Cao, J., Yang, B., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114012 · Cited by 93

CDK12: A Potent Target and Biomarker for Human Cancer Therapy

Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 76

Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma

Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 77

The Renaissance of Cyclin Dependent Kinase Inhibitors

Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 71

CDK12 and PAK2 as novel therapeutic targets for human gastric cancer

Liu, H., Shin, S. H., Chen, H., Liu, T., Li, Z., Hu, Y., Liu, F., Zhang, C., Kim, D. J., Liu, K., et al. (2020) · Theranostics · doi:10.7150/thno.46137 · Cited by 70

The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer

Tadesse, S., Duckett, D. R., & Monastyrskyi, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0240 · Cited by 58

CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells

Nilmani, D'costa, M., Bothe, A., Das, S., Kumar, S. U., Ramanathan, G., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.008 · Cited by 62

Exploring liver cancer biology through functional genetic screens

Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 58

Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer

Cheng, L., Zhou, S., Zhou, S., Shi, K., Cheng, Y., Cai, M., Ye, K., Lin, L., Zhang, Z., Jia, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0222 · Cited by 54

In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling

Romualdo, G. R., Leroy, K., Costa, C. J. S., Bacil, G. P., Vanderborght, B., da Silva, T. C., Barbisan, L. F., Andraus, W., Devisscher, L., Câmara, N. O. S., et al. (2021) · Cancers · doi:10.3390/cancers13215583 · Cited by 54

The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma

Houles, T., Boucher, J., Lavoie, G., MacLeod, G., Lin, S., Angers, S., & Roux, P. P. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01754-x · Cited by 49

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer

Lei, H., Wang, Z., Jiang, D., Liu, F., Liu, M., Lei, X., Yang, Y., He, B., Yan, M., Huang, H. W., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04027-6 · Cited by 47

Sirtuin1-p53: A potential axis for cancer therapy

Yin, J., Lu, X.-T., Hou, M.-L., Cao, T., & Tian, Z. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115543 · Cited by 44

CDK12: cellular functions and therapeutic potential of versatile player in cancer

Pilařová, K., Herudek, J., & Blažek, D. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa003 · Cited by 43

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Hou, J., He, Z., Liu, T., Chen, D., Wang, B., Wen, Q., & Zheng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.755053 · Cited by 48

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma

Houlès, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 46

Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies

Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114989 · Cited by 39

Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity

Golkowski, M. G., Lius, A., Sapre, T., Lau, H.-T., Moreno, T., Maly, D. J., & Ong, S. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.015 · Cited by 37

CDK12: a potential therapeutic target in cancer

Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.035 · Cited by 36

Acidity-Actuated Polymer/Calcium Phosphate Hybrid Nanomotor (PCaPmotor) for Penetrating Drug Delivery and Synergistic Anticancer Immunotherapy

Xu, B., Lei, H., Tong, T., Guan, Y., Wang, Y., Li, B., Zhang, S., Xing, C., Shuai, X., Huang, J., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c01610 · Cited by 32

Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma

Zhu, P., Feng, R., Lu, X., Liao, Y., Du, Z., Zhai, W., & Chen, K. (2021) · Aging · doi:10.18632/aging.202380 · Cited by 32

USP8 inhibitor–induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma

Sha, B., Sun, Y., Zhao, S., Li, M., Huang, W., Li, Z., Shi, J., Han, X., Li, P., Hu, T., et al. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09686-x · Cited by 31

Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?

Cai, X., Guillot, A., & Liu, H. (2022) · Cells · doi:10.3390/cells12010132 · Cited by 31

CDK12 regulates co-transcriptional splicing and RNA turnover in human cells

Magnuson, B., Bedi, K., Narayanan, I. V., Bartkowiak, B., Blinkiewicz, H., Paulsen, M. T., Greenleaf, A. L., & Ljungman, M. E. (2022) · iScience · doi:10.1016/j.isci.2022.105030 · Cited by 32

CDK12 orchestrates super‐enhancer‐associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer

Dai, W., Wu, J., Peng, X., Hou, W., Huang, H., Cheng, Q., Liu, Z., Luyten, W., Schoofs, L., Zhou, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1087 · Cited by 28

Artificial intelligence — upping the game in gastrointestinal endoscopy?

Rees, C. J., & Koo, S. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0178-y · Cited by 26

Current progress and novel strategies that target CDK12 for drug discovery

Lei, P., Zhang, J., Liao, P., Ren, C., Wang, J., & Wang, D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114603 · Cited by 26

MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway

Li, T.-T., Mou, J., Pan, Y., Huo, F., Du, W., Liang, J., Wang, Y., Zhang, L., & Pei, D. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00752-4 · Cited by 25

CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer

Sun, R., Wei, T., Ding, D., Zhang, J., Chen, S., He, H. H., Wang, L., & Huang, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205509119 · Cited by 26

CDK12 inhibition upregulates ATG7 triggering autophagy via AKT/FOXO3 pathway and enhances anti-PD-1 efficacy in colorectal cancer

Wu, Z., Zhang, W., Chen, L., Wang, T., Wang, X., Shi, H., Zhang, L., Zhong, M., Shi, X., Mao, X., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107097 · Cited by 25

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition

Chang, Y., Wang, X., Yang, J., Tien, J. C.-Y., Mannan, R., Cruz, G., Zhang, Y., Vo, J. N., Magnuson, B., Mahapatra, S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101752 · Cited by 24

Insights into Sorafenib resistance in hepatocellular carcinoma: Mechanisms and therapeutic aspects

Yousef, E. H., Gayar, A. M. E., & El‐Magd, N. F. A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104765 · Cited by 27

Dihydrotanshinone I targets ESR1 to induce DNA double-strand breaks and proliferation inhibition in hepatocellular carcinoma

Nie, Y., Yan, J., Huang, X., Jiang, T., Zhang, S., & Zhang, G. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155767 · Cited by 23

The mechanism of BUD13 m6A methylation mediated MBNL1-phosphorylation by CDK12 regulating the vasculogenic mimicry in glioblastoma cells

Liu, M., Ruan, X., Liu, X., Dong, W., Wang, D., Yang, C., Liu, L., Wang, P., Zhang, M., & Xue, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05426-z · Cited by 22

Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist

Mei, H., Zha, Z., Wang, W., Xie, Y., Huang, Y., Li, W., Wei, D., Zhang, X., Xie, J., Liu, J., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02513-w · Cited by 20

Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors

Yu, T., Wang, F., Li, S., Guo, W., Li, Q., Qian, Y., Li, L., Zhao, H., Zhang, Y., Gao, W., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000559 · Cited by 21

Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7

Yousef, E. H., El‐Magd, N. F. A., & Gayar, A. M. E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121735 · Cited by 20

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors

Shyamsunder, P., Sridharan, S. P., Madan, V., Dakle, P., Cao, Z., Kanojia, D., Chng, W. J., Ong, S. T., & Koeffler, H. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031207 · Cited by 18

DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity

Liu, Y., Li, Z., Zhang, J., Liu, W., Guan, S., Zhan, Y., Fang, Y., Li, Y., Deng, H., & Shen, Z. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02719-2 · Cited by 19

The dual role of p63 in cancer

Xu, Y., Yang, X., Xiong, Q., Han, J., & Zhu, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116061 · Cited by 19

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13

Ang, H. X., Sutiman, N., Deng, X., Liu, A., Cerda-Smith, C. G., Hutchinson, H. M., Kim, H., Bartelt, L. C., Chen, Q., Barrera, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221448120 · Cited by 18

CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer

Lu, K.-Q., Li, Z., Zhang, Q., Yin, Q., Zhang, Y., Ni, W., Jiang, L.-Z., He, W., & Wang, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-56831-7 · Cited by 19

Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer

Frei, K., Schecher, S., Daher, T., Hörner, N., Richter, J., Hildebrand, U., Schindeldecker, M., Witzel, H. R., Tsaur, I., Porubský, Š., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34778 · Cited by 17

Not the comfy chair! Cancer drugs that act against multiple active sites

Booth, L. A., Poklepovic, A. S., & Dent, P. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1691526 · Cited by 16

Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value

Thanindratarn, P., Dean, D. C., Feng, W., Wei, R., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2020) · European Spine Journal · doi:10.1007/s00586-020-06543-z · Cited by 15

Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy

Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors

van der Noord, V. E., van der Stel, W., Louwerens, G., Verhoeven, D., Kuiken, H. J., Lieftink, C., Grandits, M., Ecker, G. F., Beijersbergen, R. L., Bouwman, P., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01648-x · Cited by 15

Targeting PTGDS Promotes ferroptosis in peripheral T cell lymphoma through regulating HMOX1-mediated iron metabolism

Hu, S., Liu, B., Shang, J., Guo, Q., Lu, T., Zhou, X., Zhou, X., & Wang, X. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02919-w · Cited by 14

CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression

Yang, Q., & Wu, G. (2021) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2021.11.007 · Cited by 14

A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma

Farinha, D., Migawa, M. T., Sarmento‐Ribeiro, A. B., & Faneca, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s302288 · Cited by 14

Recent Developments and Evolving Therapeutic Strategies in KMT2A ‐Rearranged Acute Leukemia

Yin, L., Wan, L., Zhang, Y., Hua, S., & Shao, X. (2024) · Cancer Medicine · doi:10.1002/cam4.70326 · Cited by 13

Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519

Karaś, K., Karwaciak, I., Chałaśkiewicz, K., Sałkowska, A., Pastwińska, J., Bachorz, R. A., & Ratajewski, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115002 · Cited by 14

The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma

Wu, D., Yin, H., Yang, C., Zhang, Z.-M., Fang, F., Wang, J., Li, X., Xie, Y., Hu, X., Zhuo, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12691-y · Cited by 12

Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation

Bai, Y., Liu, Z., Li, Y., Zhao, H., Lai, C., Zhao, S., Chen, K., Luo, C., Yang, X., & Wang, F. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01697 · Cited by 12

CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway

Gao, L., Wang, J., Chen, J., Zhang, X., Zhang, M., Wang, S.-L., & Zhao, C. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04436-7 · Cited by 11

RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma

Pan, M., Sha, Y., Qiu, J., Chen, Y., Liu, L., Luo, M., Huang, A., & Xia, J. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097905 · Cited by 12

Targeting CDK12 obviates the malignant phenotypes of colorectal cancer through the Wnt/β-catenin signaling pathway

Liu, S., Wu, J., Lu, X., Guo, C., Zheng, Q., Wang, Y., Hu, Q., Bian, S., Luo, L., Cheng, Q., et al. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113613 · Cited by 10

New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy

Dai, W., Xie, D., Huang, H., Li, J., Guo, C., Cao, F., Yang, L., Zhong, C., & Liu, S. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101173 · Cited by 12

CRISPR/Cas9 genetic screens in hepatocellular carcinoma gene discovery

Chiu, C. H. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100127 · Cited by 10

Targeting Transcriptional Cyclin-Dependent Kinases in Cancer

Kołodziejczyk, A., & Siciński, P. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0677 · Cited by 9

Liensinine, a Novel and Food-Derived Compound, Exerts Potent Antihepatoma Efficacy via Inhibiting the Kv10.1 Channel

Ma, B., Shi, S., Guo, W., Zhang, H., Zhao, Z., & An, H. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c06142 · Cited by 8

Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells

Contreras, L., Rodríguez‐Gil, A., Muntané, J., & de la Cruz, J. (2022) · Cancers · doi:10.3390/cancers14051204 · Cited by 8

Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation

Díaz‐Tejeiro, C., Arenas-Moreira, M., Sanvicente, A., Paniagua‐Herranz, L., Clemente-Casares, P., Bravo, I., Alonso‐Moreno, C., Nieto‐Jiménez, C., & Ocaña, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117165 · Cited by 7

Roles of CDK12 mutations in PCa development and treatment

Jiang, C., Hong, Z., Liu, S., Hong, Z., & Dai, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189247 · Cited by 8

Are we ready for targeted therapy combinations in HCC?

Cinnamon, E., & Pikarsky, E. (2020) · Gut · doi:10.1136/gutjnl-2019-319780 · Cited by 7

An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma

Zhang, X., Jiang, M., Zhang, X., Zhang, J., Guo, H., & Wu, C. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101877 · Cited by 6

CRISPR-surfaceome: An online tool for designing highly efficient sgRNAs targeting cell surface proteins

Mei, H., Gu, Q., Wang, W., Meng, Y., Jiang, L., & Liu, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.026 · Cited by 6

CDK12 /13 dual inhibitors are potential therapeutics for acute myeloid leukemia

Savoy, L., Long, N., Lee, H., Chen, R., Allen, B., Lin, H., Tognon, C. E., Malhotra, S. V., Tyner, J. W., & Zhang, H. (2023) · British Journal of Haematology · doi:10.1111/bjh.18843 · Cited by 6

CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma

Li, Z., Li, X., Seebacher, N. A., Liu, X., Wu, W., Yu, S., Hornicek, F. J., Huang, C., & Duan, Z. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae051 · Cited by 5

Paclitaxel Overload Supramolecular Oxidative Stress Nanoamplifier with a CDK12 Inhibitor for Enhanced Cancer Therapy

Zhang, H., Xing, C., Yan, B., Lei, H., Guan, Y., Zhang, S., Kang, Y., & Pang, J. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00260 · Cited by 5

Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor

Wu, C., Ho, H. J., Wu, C., Chen, Y., Lee, T., Hsu, Y., & Lin, J. (2020) · Gut · doi:10.1136/gutjnl-2020-321932 · Cited by 5

CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma

Liu, Q., Dai, G.-R., Wang, X., Wang, L., Li, L., Wu, Z., & Xia, R.-X. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00415-4 · Cited by 5

Tubular-specific CDK12 knockout causes a defect in urine concentration due to premature cleavage of the slc12a1 gene

Wang, B., Wang, Y., Wen, Y., Zhang, Y., Ni, W., Tang, T., Cao, J.-Y., Yin, Q., Jiang, W., Yin, D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.012 · Cited by 5

Multi-omics investigation reveals functional specialization of transcriptional cyclin dependent kinases in cancer biology

Donovan, M. G., Galbraith, M. D., & Espinosa, J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-26860-1 · Cited by 5

Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities

Ju, N., Zhao, L., Yin, S., Yang, X., Zhou, J., Gao, J., & Qi, F. (2026) · International Journal of Cancer · doi:10.1002/ijc.70442 · Cited by 4

CDK12/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma

Lier, S., Markusson, S., Kocijancic, A., Narum, M., Lund, S. O., Böllering, B., Lipsa, A., Soegaard, M. D., Rein, I. D., Sántha, P., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00393-w · Cited by 4

Tubule-specific cyclin-dependent kinase 12 knockdown potentiates kidney injury through transcriptional elongation defects

Zhang, Y., Tang, T., Ni, W., Li, Z.-T., Jiang, L.-Y.-Z., Wang, Y., Zhou, X., Cao, J.-Y., Yin, Q., Jiang, W., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.90872 · Cited by 4

Caffeic acid phenethyl ester derivative exerts remarkable anti-hepatocellular carcinoma effect, non-inferior to sorafenib, in vivo analysis

Gong, L., Wang, W., Yu, F., Deng, Z., Luo, N., Zhang, X., Chen, J., & Peng, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-65496-1 · Cited by 4

Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma

Samadaei, M., Senfter, D., Madlener, S., Uranowska, K., Häfner, C., Trauner, M. A., Rohr‐Udilova, N., & Pinter, M. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30340 · Cited by 4

The role of CDK12 in tumor biology

Dzimková, M., Procházková, J., Klát, J., & Kohoutek, J. (2020) · Klinicka onkologie · doi:10.14735/amko2020260 · Cited by 3

Quest for discovering novel CDK12 inhibitor

Debnath, A., Singh, R. K., Mazumder, R., Mazumder, A., Srivastava, S., Chaudhary, H., Mangal, S., Sanchitra, J., Tyagi, P. K., Singh, S. K., et al. (2024) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2024.2441185 · Cited by 3

CDK12 inhibition enhances oxaliplatin efficacy in gastric cancer by suppressing the MAPK signaling pathway

Huang, D., Xiong, Z., Zhong, B., Li, X., Mohamed, S. A., Sun, J., Xu, H., Guo, J., Deng, Z., Li, X., et al. (2025) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2025-392 · Cited by 3

Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion

Lin, Y., Liu, H., Liao, W.-C., Wang, Y., Zhang, B.-C., Wan, S.-W., Chen, C., & Chang, C. (2025) · Oncology Reports · doi:10.3892/or.2025.8987 · Cited by 2

CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting

Dudkiewicz-Garbicz, J., & Wlodarski, P. K. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01131-z · Cited by 3

Roles of CDK12/CDK13 and development of inhibitors and degraders

Li, Z. F., Ke, Y., Zhang, R., Zhang, R., & Zhang, L. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119077 · Cited by 3

Targeting Cellular Senescence: A New Therapeutic Axis in Chronic Liver Disease

Li, J., Xiang, Z., Xu, Y., Luo, X., Jiang, Y. X., Huang, Y., Yang, Z., Chen, R., & (112147), X. X. (2026) · Engineering · doi:10.1016/j.eng.2026.02.019 · Cited by 2

Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib

Bi, Q., Deng, Z.-Q., Lv, Y., Liu, Y., Xie, C.-S., He, Y., & Tang, Q. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115593 · Cited by 2

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

Chen, B., & Liu, J. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096307629240611104728 · Cited by 2

Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12Preprint

Ang, H. X., Sutiman, N., Deng, X. L., Bartelt, L. C., Chen, Q., Barrera, A., Lin, J., Sheng, J., McDowell, I. C., Reddy, T. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.03.433762 · Cited by 2

Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma

Hu, R., Liang, X., Li, Q., & Liu, Y. Z. (2022) · Journal of Oncology · doi:10.1155/2022/4869732 · Cited by 1

3D chromatin architecture-related genes orchestrate LUAD evolution and therapy resistance: insights from integrative machine learning and spatial single-cell mapping

Jing, Y., Xing, Y., Liu, Y., Zhang, N., Pan, Y., Zhang, W., Zhu, C., Zhenyue, Z., Zhang, G., Li, J.-C., et al. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01914-z · Cited by 1

CDK12 mediates the inhibition effect of mechanical unloading on osteoblast proliferation by regulating RNAPII transcription activation

Hu, L., Zhong, W., Wang, L., Liang, S., 贾云献, Wu, Z., Shen, J., Sun, J., & Qian, A. (2026) · Bone and Joint Research · doi:10.1302/2046-3758.157.bjr-2025-0343.r1 · Cited by 1

CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression

Yang, Q., & Wu, G. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2021.11.004 · Cited by 1

Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer

Cheng, L., Zhou, S., Zhou, S., Shi, K., Cheng, Y., Cai, M., Ye, K., Lin, L., Zhang, Z., Jia, C., et al. (2023) · doi:10.1158/0008-5472.c.6514152.v1

Additional file 5 of Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist

Mei, H., Zha, Z., Wang, W. J., Xie, Y., Huang, Y., Li, W., Wei, D., Zhang, X., Qu, J., & Liu, J. (2021) · Figshare · doi:10.6084/m9.figshare.16862824

Inhibition of Cyclin‐Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy

Ardelt, M. A., Fröhlich, T., Martini, E., Müller, M. J., Kanitz, V., Atzberger, C., Huber‐Cantonati, P., Meßner, M., Posselt, L., Lehr, T., et al. (2018) · Hepatology · doi:10.1002/hep.30190 · Cited by 58

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma

Wang, C., Jin, H., Gao, D., Wang, L., Evers, B., Zheng, X., Jin, G., Lieftink, C., Beijersbergen, R. L., Qin, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0020-z · Cited by 61

Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma

Samadaei, M., Senfter, D., Madlener, S., Uranowska, K., Häfner, C., Trauner, M. A., Rohr‐Udilova, N., & Pinter, M. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30340 · Cited by 4

Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma

Wu, C. X., Wang, X. Q., Chok, K., Man, K., Tsang, S. H. Y., Chan, A. C. Y., Wing, K., Xia, W. G., & Cheung, T. T. (2018) · Theranostics · doi:10.7150/thno.25487 · Cited by 228

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma

Ehrlich, S. M. (2014) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17249